Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo

Open access
Kulkarni, Nalini H, Onyia, Jude E, Zeng, QingQiang, Tian, Xioayan, Liu, Min, Halladay, David L, Frolik, Charles A, Engler, Thomas, Wei, Tao, Kriauciunas, Aidas, Martin, T John, Sato, Masahiko, Bryant, Henry U, Ma, Yanfei L · 2006 · Journal of Bone and Mineral Research

Abstract

GSK-3, a component of the canonical Wnt signaling pathway, is implicated in regulation of bone mass. The effect of a small molecule GSK-3 inhibitor was evaluated in pre-osteoblasts and in osteopenic rats. GSK-3 inhibitor induced osteoblast differentiation in vitro and increased markers of bone formation in vitro and in vivo with concomitant increased bone mass and strength in rats. Introduction: Inactivation of glycogen synthase kinase −3 (GSK-3) leads to stabilization, accumulation, and translocation of β-catenin into the nucleus to activate downstream Wnt target genes. To examine whether GSK-3 directly regulates bone formation and mass we evaluated the effect of 603281-31-8, a small molecule GSK-3 α/β dual inhibitor in preosteoblastic cells and in osteopenic rats. Materials and Methods: Murine mesenchymal C3H10T1/2 cells were treated with GSK-3 inhibitor (603281-31-8) and assayed for β-catenin levels, activity of Wnt-responsive promoter, expression of mRNA for bone formation, and adipogenic markers and alkaline phosphatase activity. In vivo, 6-month-old rats were ovariectomized (OVX), allowed to lose bone for 1 month, and treated with GSK-3 inhibitor at 3 mg/kg/day orally for 60 days. At the end of treatment, BMD was measured by DXA, bone formation rate by histomorphometry, vertebral strength (failure in compression), and the expression levels of osteoblast-related genes by real-time PCR. Results: Treatment of C3H10T1/2 cells with the GSK-3 inhibitor increased the levels of β-catenin accompanied by activation of Wnt-responsive TBE6-luciferase reporter gene. This was associated with an increased expression of mRNA for bone sialoprotein (1.4-fold), collagen α1 (I) (∼2-fold), osteocalcin (1.2-fold), collagen α1(V) (1.5-fold), alkaline phosphatase (∼160-fold), and runx2 (1.6-fold), markers of the osteoblast phenotype and bone formation activity. Alkaline phosphatase mRNA expression paralleled alkaline phosphatase activity. The mRNA levels of collagens α1 (I), α1 (V), biglycan, osteonectin, and runx-2 increased on treatment with the GSK-3 inhibitor in rat femur compared with the OVX control. DXA analyses revealed significant increases in BMC and BMD in cancellous and cortical bone of OVX rats treated with GSK-3 inhibitor. This was associated with increased strength (peak load, energy, and stiffness) assessed by lumbar vertebra load to failure in compression. Histomorphometric analyses showed that 603281-31-8 robustly increased bone formation but did not exclude a small effect on osteoclasts (resorption). Conclusions: An orally active, small molecule GSK-3 inhibitor induced osteoblast differentiation and increased markers of bone formation in vitro, and increased markers of bone formation, bone mass, and strength in vivo, consistent with a role for the canonical Wnt pathway in osteogenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1359/jbmr.060316

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 182

Metadata

Authors
Kulkarni, N. H., Onyia, J. E., Zeng, Q., Tian, X., Liu, M., Halladay, D. L., Frolik, C. A., Engler, T., Wei, T., Kriauciunas, A., Martin, T. J., Sato, M., Bryant, H. U., & Ma, Y. L.
Venue
Journal of Bone and Mineral Research
Published
2006-06-01
Volume
21
Issue
6
Pages
910-920
ISSN
  • 0884-0431 (ISSN-L)
  • 1523-4681
OpenAlex
W2076587628
Cited by
182
References
6
FWCI
6.02
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo. https://app.cochat.ai/papers/10.1359/jbmr.060316
The paper
Kulkarni, N. H., Onyia, J. E., Zeng, Q., Tian, X., Liu, M., Halladay, D. L., Frolik, C. A., Engler, T., Wei, T., Kriauciunas, A., Martin, T. J., Sato, M., Bryant, H. U., & Ma, Y. L. (2006). Orally Bioavailable GSK-3α/β Dual Inhibitor Increases Markers of Cellular Differentiation In Vitro and Bone Mass In Vivo. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.060316

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.